LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

Kodu・Aktsiate loetelu・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Avatud

SektorTervishoid

9.2 2.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.91

Max

9.38

Põhinäitajad
By Trading Economics
Sissetulek	61M 6.8M
Müük	7.4M 156M
P/E Sektori keskmine	8.634 50.102
Aktsiakasum	0.21
Kasumimarginaal	4.356
Töötajad	900
EBITDA	28M 35M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+33.33% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	21M 436M
Eelmine avamishind	6.75
Eelmine sulgemishind	9.2

Uudiste sentiment

By Acuity

100%

323 / 344 Pingereas Healthcare

Emergent BioSolutions Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. mai 2026, 22:47 UTC

Tulu

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28. mai 2026, 20:45 UTC

Tulu

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28. mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28. mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28. mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28. mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28. mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28. mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28. mai 2026, 22:37 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

M&A-Related Insurance Payments In North America Rise -- Market Talk

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28. mai 2026, 21:12 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28. mai 2026, 21:00 UTC

Tulu

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28. mai 2026, 20:57 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:55 UTC

Tulu

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28. mai 2026, 20:48 UTC

Kuumad aktsiad

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28. mai 2026, 20:34 UTC

Tulu

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28. mai 2026, 20:31 UTC

Tulu

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28. mai 2026, 20:28 UTC

Tulu

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28. mai 2026, 20:26 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Membership Fees $1.37B

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Net Sales $69.15B

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Same-Store Sales Up 9.8% >COST

Võrdlus sarnastega

Hinnamuutus

Emergent BioSolutions Inc Prognoos

Hinnasiht

By TipRanks

33.33% tõus

12 kuu keskmine prognoos

Keskmine 12 USD 33.33%

Kõrge 12 USD

Madal 12 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Emergent BioSolutions Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Emergent BioSolutions Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

323 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.